reason report
receptor inhibit treat diseas initi op pt
bottom line initi coverag op rate
pt leverag proprietari small molecul inhibitor
librari target chemoattract chemokin receptor believ
play import role diseas see sever mileston
next yr start advoc data
anca-associ vasculitis/aav trail
glomerulopathi hidraden suppurativa hs data
subsequ quarter binari catalyst expect pre-
commerci biotech compani like assum posit
data materi could disruptor sever target
indic lack approv effect standard care soc
drug candid multipl market opp tie lead asset
avacopan multipl mid- late- stage clinic studi
believ aav hs could repres opp ty addit
posit data aav believ competitor data
ifrx op offer read-through de-risk avacopan
drug share similar target earlier-stag drug
focal segment glomerulosclerosi fsg lead indic
fsg also present opp ty think
inhibit mechan may use indic multipl
opp tie see valuat attract buy
chang trial design add risk advoc posit outcom
could challeng current soc aav although soc high dose steroid
cyclophosphamid rituximab readili avail remiss
rate high medacorp kol note relaps rate poor
complianc toxic weak base data believ
avacopan could dramat alter soc deliv clinic efficaci
bva decreas lower steroid burden howev chang
introduc advoc trial includ trial design durat
base bva add risk head data readout
cautious optimist posit outcom ascrib
probabl success po ww mind risk associ
non-inferior trial yet posit believ aav repres
attract market estim peak sale us alon
acceler develop possibl hs
fsg may take time although ground limit
data management believ hs may also benefit avacopan
mechan rel larg studi way
indic may registr meanwhil believ
shine data ifrx could de-risk avacopan prior data
contrast despit attract market oppti fsg exist data
uncertain regulatori expect less clear pend
data studi cautiou ascrib po ww
blend revenu multipl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
break-up receptor inhibit treat diseas init op pt
market close
market cap compani focus rare diseas initi deliv oral administ chemoattract
chemokin receptor inhibitor
though defin orphan indic believ anca-associ vascul aav hidraden suppurativa
earlier-stag asset expand applic proprietari small molecul platform target preval
diseas like inflammatori bowel diseas ibd cancer
kidney partnership vifor pharma vifn expand global reach drug approv without signific
invest commerci footprint
compani led founder presid ceo thoma schall ph pioneer chemokin research
respons discoveri co-discoveri known chemokin receptor
cusp becom commerci compani seri key data catalyst
start
pend posit data agent could becom re-defin standard care soc
 program underway believ aav hs fsg repres opportun
peak current valuat offer attract entri point view
avacopan target complement system alxn op success set posit preced
founder ceo expertis chemokin biolog strong asset organ growth
beyond avacopan ccxi platform small molecul inhibitor gener long-
deriv one-year pt base
blend dcf analysi revenu multipl
analysi assign valu probability-weight sale
avacopan po anca-associ vascul
aav glomerulopathi
hidraden suppurativa hs sale
po focal segment glomerulosclerosi
fsg addit indic
clinic asset earlier-stag candid repres
upsid estim matur clinical-stag
compani use discount rate termin
npv net impli market cap dcf valuat discount rate/cost growth outstand mm revenu multipl blend pt chemocentryx dcf cf net borrowing- inc
risk valuat
clinical-stag compani risk includ clinic regulatori financi
 lead asset avacopan add signific binari risk head data readout even though
evalu multipl indic guarante program succeed
 understand complement system diseas still evolv success particular
indic may translat success indic
 clinic risk associ clinic candid
fda remain accommod rare diseas drug
increasingli influenti patient voic drug
develop help trial design conduct
breakthrough genet evolut
biomark increas odd success
cost-effect faster drug develop
diseas drug insul price scrutini
competitor data ifrx de-risk
program aav hs
despit theoret risk complement inhibit
safeti profil favor thu far select
upsid first-to-market develop
despit success soliri much
complement biolog remain elucid
favor promis preclin data
interpret caution
distinct drug profil may emerg base drug
competit rare diseas rais risk trial delay
small patient popul diseas heterogen
may elev risk failur
within microenviron without trigger
safeti concern remain determin tbd
could gateway
estim preval us eu patient see aav
 standard care steroid immunosuppress cyclophosphamide/cyc rituximab/rtx
effect improv desir safety/toler soc remiss rate high
month toxic side effect limit long-term use steroid hamper patient complianc
 relaps rate high despit high rate remiss certain aav patient
succumb high rate relaps toler effect treatment regimen desir
 modest price peak penetr assumpt us could render
blockbust opportun aav medacorp kol believ reduc steroid regimen could facilit
market uptak may conserv could also avoid payor scrutini
 partnership vifor could help ex-u market penetr royalti rang teen mid-
twenti addit variou mileston payment model
kidney health allianc vifor
commerci right europ
certain intern market
avacopan anca-associ vascul aav background
less often medium-s arteri vein
organ affect includ kidney lung ear nose throat
mechan
one cleav product complement
inhibitor target receptor
standard
preval per million us eu
incid per million us eu
soc steroid cyclophosphamid cyc rituximab
azathioprin methotrex may replac cyc mainten
enrol complet phase advoc trial juli
top-line data expect
pend satisfactori progress nda submiss guid
phase studi avacopan lower need steroid treatment
still deliv clinic benefit aav patient
primari endpoint decreas bva baselin
treatment effect variabl
sustain efficaci bva discontinu avacopan
treatment low steroid steroid week
 remiss data week also support benefit avacopan
qualiti life
albumin/creatinin rapid sustain improv may translat preserv renal function
monocyt chemoattract protein reduct inflamm biomark may
qualiti life qol
patient-report outcom show greater improv associ avacopan
lower incid advers event relat glucocorticoid use also plu
preclin valid target complement particularli
effect anim model
compon effect abolish develop key abnorm
downstream specif block led better outcom irrespect time
intervent
within complement system receptor stand
drug target
evid support receptor drug target
aav mous model lack receptor
protect mice diseas lower crescent necros
hallmark diseas detect compar wt
right top better kidney health associ
like attribut fewer glomerular neutrophil infiltr
compar wt -- highlight brown stain
evid support ligand drug target
right bottom human plasma level significantli
higher patient activ aav diseas compar
healthi individu patient remiss
target cognat receptor attenu
downstream effect consequ
despit neutrophil involv failur anti-tnf- approach pave
way avacopan becom first approv aav treatment
complement involv immunosuppress benefici potenti
vitro tnf- could equal robustli activ neutrophil
current aav standard care soc also includ immunosuppress cyclophosphamid
howev anti-tnf- clinic data aav leav room improv
studi infliximab adalimumab open-label uncontrol
differ definit remiss primari endpoint obfusc trial comparison
long-term relaps rate question valu treatment
anti-tnf- drugtrial phasecontrol armenrollmentbaselin bvasprimari endpointrespons ratestudi ii humira within first bva remicad etanercept enbrel least inc
upcom phase advoc data could set stage
progress remain on-track avacopan aav
phase advoc studi fulli enrol data expect
assum timelin assum
us market entri possibl
competit landscap avacopan look lead aav
accord clinicaltri gov drug late-stag develop
avacopan advoc studi lead top-line data expect
share mechan would suggest target ligand vs receptor avacopan
though phase could de-risk avacopan data
may greater competit threat long-run
list tabl numer studi evalu rituximab steroid well
estim preval us eu patient smaller
untap market though riski avacopan may expedit file pathway
 lack clear soc could benefit uptak first approv therapi due recent re-definit
diseas treatment regimen physician discret complet remiss cr
rare relaps rate high
 limit evid support soliri use unclear rational payor pushback repres
signific hurdl despit success stori factor determin respond poorli
defin fact soliri cost high high pushback payor off-label use
commit develop program limit patient access drug
 model modest price peak penetr assumpt us
despit invas diagnosi first-in-diseas statu could reward handsom price
assumpt lower price could provid upsid
 partnership vifor could help ex-u market penetr royalti rang teen mid-
twenti addit variou mileston payment model
kidney health allianc vifor
commerci right europ
certain intern market
avacopan glomerulopathi background
character promin glomerular deposit
scant immunoglobulin presenc kidney glomeruli
previous classifi either dens deposit diseas
mechan
one cleav product complement
inhibitor target receptor
standard
preval us eu
incid us eu new case per year
soc blood pressur control immunosuppress
anecdot report soliri eculizumab show efficaci
anticip enrol complet phase trial
top-line data anticip time point
yield better result chronic therapi appear necessari
key
 drug benefit
lost
benefit
eculizumab experi consist murin data
support role complement
among patient benefit eculizumab diseas rebound upon cessat treatment
 patient creatinin elev mg/dl mg/dl week restart eculizumab
 patient creatinin elev mg/dl week recurr activ crescent
diseas onset patient therapeut benefit eculizumab less clear
 show declin renal function treatment diseas histori year year
 remain patient shorter diseas histori rang month
build data antagon anim shown
promis question remain
mice lack green rectangl show
 death diseas induct vs death mice
 mice protect albuminuria diseas onset
posit stain less cell neutrophil
 interestingli signific differ hematuria bottom right
 mous model repres prophylaxi on-demand
 long-term implic consequ posit stain
 occup achiev avacopan
market avacopan
although label phase larg trial could registr
 primari endpoint consist histolog index chi month
chi fairli new howev suffici power see certain percentag chang
 secondari endpoint includ urinari protein creatinin qualiti life qol
serum creatinin measur egfr
 risk lack preced could howev call subsequ study/studi
 specif segreg dens deposit diseas glomerulonephr patient
uncertain whether treatment effect differ base underli diseas
 fundament involv neutrophil kidney necrosi could make avacopan effect
competit landscap achillion commit mechan pose
greatest threat avacopan
achn ahead well-capit could versatil compound librari
 alreadi gener preliminari phase data effect biomark link
 global site open increas patient enrol
 gener compound quickli advanc compound
proprietari librari could gener shots-on-go
omer prospect remain seen
 progress larg iga nephropathi igan although phase studi includ
 phase artemis-igan plan final statu updat remain determin
daratumumab threat appear less like materi
 investigator-l trial may/may transpir full phase trial
clinicaltri gov compani websit present svb leerink research estim
phase clinic studi underway humira serv ideal comp hs
 moderate-sever patient us eu hs larger rare diseas
preval may still underestim improv diseas awar could uncov addit
patient moderate-sever hs patient consid refractori soc
 humira soc unmet need remain outcom could de-risk avacopan
potenti replac soc data humira-tr patient respond
efficaci wane upon longer durat treatment avacopan target ligand
receptor could replac soc base share biolog mechan shine data
link could de-risk avacopan hs
 model modest price peak penetr assumpt us
eu us eu us price assumpt like lower humira
link posit data emerg higher avacopan price could offer upsid stock current
assum us/eu price
recogn hs revenu
avacopan hidraden suppurativa hs background
hidraden suppurativa hs also known acn inversa
character recurr nodul abscess fistula
mechan
one cleav product complement
posit phase data ifrx de-risk avacopan base
share mechan
standard
preval us eu
soc humira adalimumab approv hs
regard moder efficaci respons rate
top-line data expect data potenti
believ data de-risk avacopan hidraden
select target ligand without compromis format
membran attack complex see ifrx initi link
 phase show rapid sustain respons moderate-sever patient
hard-to-treat entri particip either fail inelig biolog treatment
seriou treatment-emerg advers event teae none related/unlik relat
continu increas time
target could competit current standard
humira-tr patient respond week
yet among respond efficaci wane long-term treatment
avacopan
weekli iv infus could better treatment option humira
although across cohort neg impact studi power phase shine studi could
unlik shine avacopan trial week durat similar humira pioneer
shine top-line data expect ahead avacopan hs
 target theoret deliv similar efficaci profil shine data could de-risk
avacopan phase studi hs underway
 primari endpoint proport patient clinic respons hiscr week
week durat pioneer studi shorter phase shine studi
 secondari endpoint includ hs qualiti life instrument hisqol among other
 believ registration-grad trial
 ifrx shine studi complet enrol less risk patient recruit delay
 preliminari guidanc data readout
differ clinic efficaci
block receptor potenti benefici downstream effect may also neg affect
may still interact receptor role remain controversi ie pro- anti-inflammatori
read-through avacopan
pend avacopan data hs offer closest read-through
phase shine studi aim reproduc success phase studi
data expect could provid read-through avacopan hs
investig agent consist anti-inflammatori agent efficaci durabl vi --
vi humira worth watch
although address differ target secukinumab bermekimab bimekizumab guselkumab
 bermekimab report mix phase data efficaci week could perceiv humira-
like safeti rais question hs exacerb
 unclear secukinumab cosentyx competit phase initi guid
inhibitor could also show efficaci safeti profil watch
drugmoasponsorphasecomplet date estimate june inc
antagon
although behind op sparsentan effect fsg treatment could open
 preval estim us/eu like conserv improv diseas
 behind sparsentan emerg competit landscap unlik first-to-market
favor drug profil could still captur meaning market share on-going studi suggest
least competitor bardoxolon op voclosporin auph op leverag distinct
mechan think fsg market may accommod multipl agent
 model price peak penetr assumpt us us
price assumpt on-par sparsentan assumpt
 partnership vifor could help ex-u market penetr royalti rang teen mid-
twenti addit variou mileston payment model
kidney health allianc vifor
commerci right europ
certain intern market
focal segment glomerulosclerosi fsg background
renal failur podocyt loss glomerular sclerosi
mechan
known dysregul kidney diseas includ fsg
standard
preval us eu
soc high dose steroid and/or immunosuppress
non-specif treatment aim control proteinuria
phase trial underway nephrot syndrom link sub-
preliminari guidanc top-line data
preclin model corrobor inhibit fsg
inhibit result
two differ mous model
mice adriamycin induc
bun cystatin also reduc
inhibit effect either
monotherapi ad
raa blocker
endothelin receptor/angiotensin
receptor blockad dual
mechan current phase
duplex interim data
experiment shown potent specif antagonist nm
vs vehicl vs raa blocker
vs vehicl vs raa blocker
howev inhibit diabet nephropathi patient rais
question fsg program
 lack dose effect
higher albuminuria reduct week among treat patient
mg mg vs pbo
albuminuria risk end stage
compar safeti profil treat pbo arm
high patient complianc
albuminuria reduct less threshold suggest
meaning meta-analysi reduc esrd risk
lack dose-respons possibl wane efficaci
measur egfr blood urea nitrogen bun
urinari significantli differ vs pbo
whether diabet nephropathi result translat fsg
convers valid fsg may open door
orphan kidney indic alport syndrom
potenti role alport syndrom
situ hybrid kidney section alport
upregul alport mice dog
patient
select inhibit improv
benefit inhibit
arrow head podocyt foot process slit diaphragm
phase fsg studi could defin path forward
phase trial target distinct patient could defin regulatori path
 trial target fsg patient nephrot syndrom g/day baselin proteinuria link
 trial target fsg patient sub-nephrot syndrom g/day baselin proteinuria link
 establish threshold approv endpoint
 nephrot syndrom fda kol believ reduct proteinuria sub-nephrot rang
 would clinic meaning
 posthoc analysi diabet nephropathi data highest third patient mg
proteinuria saw reduct
could bode well nephrot syndrom studi
competit landscap multipl competitor fsg develop
horizon led retrophin sparsentan
phase asset sparsentan op clear leader numer candid advanc
phase includ
fsg data expect bardoxolon phase phoenix studi
share common mechan inhibit could de-risk
believ reduct proteinuria valid clinic endpoint
sparsentan valid proteinuria clinic meaning endpoint
reduct proteinuria also adopt fsg clinic trial bardoxolon op
proteinuria reduct approv endpoint eye sparsentan
phase duplex studi
sparsentan preced fsg
phase duet studi proteinuria reduct higher among
modifi partial remiss mpr complet remiss cr also
higher sparsentan cohort
meanwhil estim glomerular filtrat rate egfr remain
stabl sparsentan treatment
fda endors proteinuria reduct approv
endpoint acceler approv
sparsentan path approv
avacopan antagon downstream complement cascad
howev juri whether ligand receptor
attract downstream complement target
target effect minim side effect expect inhibit upstream
target leav format membran attack complex intact therebi
reduc infect risk associ eculizumab therapi
theoret concern surround antagon intern and/or
upregul express
induc sepsi model intern neutrophil intern receptor
difficult target cell surfac
upregul follow inflamm may requir higher dose drug full
biolog downstream output
predominantli express
monocyt mediat tissu influx
context immune-bas inflamm
also known
dendrit cell site inflamm
express cell type well
 constitut express human
multipl downstream output possibl
liver inflamm
attribut signal
pend demonstr favor efficaci safeti strong patent
 composit matter com us eu
pend applic cover synthet method make avacopan grant
 composit matter com us eu
 composit matter com us
patent applic target
founder chemocentryx
thoma schall ph presid ceo chairman board
ph cancer biolog stanford univers
bba univers california berkeley
marku cappel ph chief busi offic treasur
ph pharmaceut goeth univers harvard busi school
jan hilson svp drug develop
zymogenet xcyte therapi harvard medic school/cambridg allianc univers
rajind singh ph svp research
ph organ chemistri univers oxford
collabor licens revenu
total incom expens
chang cash
proce common stock
proce convert note/debt
proce warrant
discount rate/cost equiti
treat corticosteroid cyclophosphamid
patient soc
remiss rate soc
elig patient altern treatment
treat avacopan
treat avacopan
treat corticosteroid cyclophosphamid
patient soc
remiss rate soc
elig patient altern treatment
treat avacopan
treat avacopan
royalti rate
royalti paid
royalti rate eu
probabl success po us
probabl success po eu
treat soc us
treat soc eu
remiss soc us
remiss soc eu
preval per us
proport popul
gain-of-funct mutat
progress esrd
proport popul
gain-of-funct mutat
progress esrd
penetr
penetr avacopan
proport popul
gain-of-funct mutat
progress esrd
proport popul
gain-of-funct mutat
progress esrd
penetr
penetr avacopan
royalti rate
royalti paid
preval per us
royalti rate eu
probabl success po us
probabl success po eu
gof mutat
progress esrd
preval hs us
refractori treatment us
penetr
penetr avacopan
preval hs eu
refractori treatment eu
penetr
penetr avacopan
probabl success po us
probabl success po eu
patient nephrot syndrom
patient subnephrot syndrom
penetr sparsentan
penetr avacopan
patient nephrot syndrom
patient subnephrot syndrom
penetr sparsentan
penetr avacopan
royalti rate
royalti paid
royalti rate eu
probabl success po us
probabl success po eu
sourc rosenberg az kopp jb clin soc nephrol compani file compani present svb leerink research
